En
The Young Scientists Network (YSN) of the European Federation of Medicinal Chemistry and Chemical Biology (EFMC) decided to launch MedChemBioOnline, a series of webinars which will mix science, soft-skills trainings and round table discussions.
Organized every three months on a free-to-attend basis, the 2,5 hours webinars aims to meet the current needs of our scientific community to continue interacting and sharing ideas and innovation, as well as providing early career scientists with opportunities to listen to outstanding scientists and expand their knowledge.
What do you want to see next?
We are really keen to hear your feedback, receive ideas for soft-skill trainings or speakers' suggestions.
Please get in touch with us:
Interested in becoming the exclusive sponsor of the event?
Reach out to us at
The schedule and topics of the 2023 EFMC-YSN MedChemBioOnline will be announced soon!
TOPIC: Successful Stories of Women in Science: Inspiring Career Paths
Chair:
Dr Chiara BORSARI (University of Milan, Italy)
Moderator:
Dr Caroline LANTHIER (University of Antwerp, Belgium)
The programme of the webinar will be as follow:
The event is free and open to everyone thanks to the support of Journal of Medicinal Chemistry and ACS Medicinal Chemistry Letters.
The Journal of Medicinal Chemistry and ACS Medicinal Chemistry Letters are published by ACS Publications, a nonprofit society publisher and a division of the American Chemical Society. ACS also supports the global community of scientific researchers through digital books and courses from the ACS Institute.
TOPIC: Chemical Biology as a Bridge Between Industry and Academia
Chairs:
Dr Maria DUCA (University of Côte d'Azur, France) @EFMC Chemical Biology Initiative
Dr Clemens ZWERGEL (University of Rome "La Sapienza", Italy) @EFMC Young Scientists Network
The programme of the webinar will be as follow:
Registration to the event is free and open to all thanks to the generous support of Symeres.
For over 30 years, the world’s leading life sciences companies have made Symeres part of their team. From hit generation and lead optimization, ADME-Tox via our Admescope organization, through to complex route development and clinical supply, we help to create safe, innovative therapies. We make molecules matter. Together.
TOPIC: Covalent Chemical Probes and Drugs
Chair
Dr Chiara BORSARI (University of Basel, Switzerland)
Moderator
Dr Caroline LANTHIER (University of Antwerp, Belgium)
The programme of the webinar will be as follow:
Registration to the event is free and open to all thanks to the generous support of WuXi AppTec.
As a global company with operations across Asia, Europe, and North America, WuXi AppTec provides a broad portfolio of R&D and manufacturing services that enable global pharmaceutical and healthcare industry to advance discoveries and deliver groundbreaking treatments to patients.
TOPIC: Late Stage Functionalisation
Chair
Dr Michele MARI (University of Urbino Carlo Bo, Italy)
The programme of the webinar will be as follow:
TOPIC: What Can the Medicinal Chemists Learn from Data Sciences?
Chairs
Dr Filipa RAMILO GOMES (F. Hoffmann-La Roche, Switzerland) @ EFMC Young Scientists Network
Dr Franz VON NUSSBAUM (Nuvisan, Germany) @ EFMC² Computational Chemistry Initiative
The programme of the webinar will be as follow:
Registration to the event is free and open to all thanks to the generous support of Symeres.
For over 30 years, the world’s leading life sciences companies have made Symeres part of their team. From hit generation and lead optimization, ADME-Tox via our Admescope organization, through to complex route development and clinical supply, we help to create safe, innovative therapies. We make molecules matter. Together.
TOPIC: Biological Testing of Hit Compounds
Chair
Dr Chiara BORSARI (University of Basel, Basel, Switzerland)
Moderator
Ms Marta PIQUERO (University of Basel, Basel, Switzerland)
The programme of the webinar will be as follow:
The event is free and open to all thanks to the generous support of our sponsors.
 |
 |
|
Pivot Park Screening Centre (PPSC) is your optimal partner in early drug discovery. At PPSC we provide drug discovery services in Assay Development, ultra-High-Throughput Screening (uHTS), Mass Spectrometry Screening and Hit-to-lead Profiling to find novel leads for drug development. PPSC is located at Pivot Park Life Sciences Campus in Oss, The Netherlands. Learn more at https://www.ppscreeningcentre.com/ |
Servier is a global pharmaceutical group governed by a Foundation, with a strong international presence in 150 countries and 22,500 employees worldwide. A leader in cardiology, our ambition is to become a renowned and innovative player in oncology for the benefit of patients.
The Group is committed to open and collaborative innovation with academia, pharmaceutical groups, and biotech companies. More information: servier.com |
|
|
|
|
Sanofi is dedicated to supporting people through their health challenges. We are a global biopharmaceutical company focused on human health. With more than 100,000 people in 100 countries, Sanofi is transforming scientific innovation into healthcare solutions around the globe. More information: www.sanofi.com |
Recordings are available on the EFMC YouTube Channel.
TOPIC: Validating Chemical Probes
Chairman
Dr Etienne Donckele (Monte Rosa Therapeutics, Switzerland)
Moderator
Matic Proj (University of Ljubljana, Slovenia)
The programme of the webinar will be as follow:
The event is free and open to all thanks to the generous support of Symeres.
Symeres is the leading mid-sized European Contract Research Organization for your drug discovery and development needs. With over 500 scientists, we offer best-in-class solutions from early-stage hit finding to the delivery of your early clinical drug substance API, for small- to medium-sized molecules.
« Keynote speaker has changed, do not miss this amazing opportunity to meet Paul Brennan from the University of Oxford »
TOPIC: Present and Future of Epigenetics
Chairman
Dr Clemens Zwergel (Sapienza University of Rome, Italy)
Moderator
Dr Caroline Lanthier (University of Antwerp, Belgium)
The programme of the webinar will be as follow:
The event will be free and open to all thanks to the generous support of Reaction Biology.
Reaction Biology is an industry leader offering contract research for epigenetic drug discovery. We have a reputation for providing high quality data generated by gold standard activity and binding assays. Via flexibility for custom-tailored solutions and direct communication with our clients we address the goals of every individual research project.
Replays available on YouTube!
TOPIC: PROTAC and Small Molecules Development
Chairwoman
Dr Chiara Borsari (University of Basel, Switzerland)
Moderator
Mr Matic Proj (University of Ljubljana, Slovenia)
PROGRAMME:
The event was generously supported by Symeres.
Symeres is the leading mid-sized European Contract Research Organization for your drug discovery and development needs. With over 500 scientists, we offer best-in-class solutions from early-stage hit finding to the delivery of your early clinical drug substance API, for small- to medium-sized molecules.
TOPIC: Artificial Intelligence applied to Medicinal Chemistry
Chairwoman
Dr Kristina Goncharenko (Spirochem, Switzerland)
Moderator
Dr Filipa Ramilo Gomes (Instituto Superior Técnico, University of Lisbon, Portugal)
PROGRAMME:
The event was generously sponsored by Schrödinger.
To improve human health and quality of life by transforming the way therapeutics and materials are discovered.
RECORDING AVAILABLE: By clicking on "video" next to the title of each talk, you will be directed to the corresponding recording available on the EFMC YouTube Channel.
PROGRAMME:
Chairwoman
Dr Filipa Ramilo Gomes (Instituto Superior Técnico, University of Lisbon, Portugal)
Moderator
Dr Leire Iralde Lorente (University of Siena, Italy)
RECORDING AVAILABLE: By clicking on "video" next to the title of each talk, you will be directed to the corresponding recording available on the EFMC YouTube Channel.
PROGRAMME:
Chairwoman
Dr Kristina Goncharenko (Spirochem, Switzerland)
Moderator
Mrs Caroline Lanthier (University of Caen Normandy, France)
Synple Chem is a developer of new organic synthesis technologies. Our automated capsule-based synthesizers work analogously to capsule coffee makers - simply add the starting material and a commercially available, single-use, disposable reagent capsule, then with a single touch of a button, the product is generated, isolated and purified!
RECORDING AVAILABLE: By clicking on "video" next to the title of each talk, you will be directed to the corresponding recording available on the EFMC YouTube Channel.
PROGRAMME:
Chairman
Dr Clemens Zwergel (Sapienza University of Rome, Italy)
Moderator
Mr Matic Proj (University of Ljubljana, Slovenia)
MercachemSyncom is the leading mid-sized European drug-discovery CRO for solving your chemistry challenges, from small to medium-sized molecule hits, to the first GMP batches of identified clinical candidates. We blend vast scientific knowledge with inventiveness to make great leaps on your behalf. We go further to unlock new potential.
Recording/Presentations available: By clicking on the title of each talk, you will be directed to the corresponding recording available on the EFMC YouTube Channel, or access the slide deck when a recording is not available.
PROGRAMME:
Chairman
Dr Michele Mari (Università degli Studi di Urbino Carlo Bo, Italy)
Moderator
Ms Pauline Zipfel (University of Caen Normandy, France)
The event was generously sponsored by WuXi AppTec.
Established in December 2000, WuXi AppTec provides a broad portfolio of R&D and manufacturing services to advance discoveries and deliver groundbreaking treatments to patients. WuXi AppTec HitS Unit provides a one-stop Target-to-Hit services that enable companies in the pharmaceuticals, biotech and academics worldwide to seek premium drug discovery. With industry-leading capabilities such as protein science, biophysics, DNA-encoded library technology, and structure-based drug design, HitS is committed to drive toward the realization of the vision that every drug can be made and every disease can be treated.
